In this shifting healthcare paradigm and with emerging technology, such as liquid biopsies and multiplexing, generating novel biomarker signatures that are demonstrating their predictive power for patient selection, treatment and resistance monitoring, now is the time to harness a fully fledged biomarker-diagnostic platform to efficiently bring your targeted drug candidates to market.
Within oncology, competition is fierce for specific patient populations and in non-oncology indications (such as cardiovascular, CNS, autoimmune and rare diseases) the role of biomarker-based diagnostics are starting to prove their value.
Attend World CDx Boston 2017 to discover the very latest data proving their clinical utility in responder selection and outcome monitoring.
World CDx Boston 2017 will also showcase industry-defining discussions on the strategic challenges facing the real world application of precision medicines and companion diagnostics to specific patients in need. Uncover solutions to key challenges including revamping reimbursement strategy to focus on clinical outcomes, selecting the most appropriate and fit for purpose CDx platform to maximize real-world adoption and gaining buy-in from physicians and patients alike.
Be at the pinnacle of crucial and candid conversation to discover why, how and when to adopt a CDx strategy early in your drug development programs and ensure you have the right collaboration to ultimately deliver a CDx strategy that brings true value to the market penetration and share of your drug.
For exclusive updates and to be the first to receive our agenda, please register your interest below
Check out what happened at our last CDx event